SGN-35C: A Novel CD30-Directed Antibody-Drug Conjugate for the Treatment of Lymphomas

被引：3
|
作者：
Hamblett, Kevin J. [1 ]
Cochran, Julia [1 ]
Snead, Katie [1 ]
Jin, Steven [1 ]
Yumul, Roma [1 ]
Simmons, Jessica [1 ]
Stone, Ivan [1 ]
Lyski, Ryan [1 ]
Schrum, Jason P. [1 ]
Lim, Andrea R. [1 ]
Clarke, Astrid [1 ]
机构：
[1] Seagen Inc, Bothell, WA USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-182400
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pharmacokinetic-Pharmacodynamic Modeling of the Antitumor Effects of SGN-CD19A, a Novel Antibody-Drug Conjugate, in Mice
    Zhao, Baiteng
    Stevison, Faith
    Law, Che-Leung
    Han, Tae H.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S17 - S18
  • [22] BRENTUXIMAB VEDOTIN (SGN-35), AN ANTIBODY-DRUG CONJUGATE, DOES NOT AFFECT MIDAZOLAM PHARMACOKINETICS.
    Han, T. H.
    Grove, L. E.
    Lynch, C. M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 : S52 - S52
  • [23] In the spotlight: a novel CD37 antibody-drug conjugate
    Palomba, M. Lia
    Younes, Anas
    BLOOD, 2013, 122 (20) : 3397 - 3398
  • [24] Brentuximab vedotin: An anti-CD30 antibody-drug conjugate
    Bradley, Amber M.
    Devine, Meghan
    DeRemer, David
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2013, 70 (07) : 589 - 597
  • [25] The Antibody-Drug Conjugate Brentuximab Vedotin (SGN-35) Induced Multiple Objective Responses in Patients with Relapsed or Refractory CD30-Positive Lymphomas in a Phase 1 Weekly Dosing Study.
    Fanale, Michelle
    Bartlett, Nancy L.
    Forero-Torres, Andres
    Rosenblatt, Joseph
    Horning, Sandra J.
    Franklin, Anna R.
    Lynch, Carmel M.
    Sievers, Eric L.
    Kennedy, Dana A.
    BLOOD, 2009, 114 (22) : 1068 - 1069
  • [26] Model-based alternative clinical trial designs and evaluations for SGN-CD19A, a novel antibody-drug conjugate
    Zhao, Baiteng
    Albertson, Tina M.
    Law, Che-Leung
    O'Meara, Megan M.
    Kostic, Ana
    Han, Tae H.
    CANCER RESEARCH, 2014, 74 (19)
  • [27] SGN-CD19A: A novel Anti-CD19 antibody drug conjugate
    Albertson, Tina M.
    Sandalic, Lali
    Zhao, Baiteng
    Kostic, Ana
    Law, Che-Leung
    CANCER RESEARCH, 2014, 74 (19)
  • [28] ACTIVITY, SAFETY AND TOLERABILITY OF ANTIBODY-DRUG CONJUGATE (ADC) SGN-35 IN RELAPSED/REFRACTORY (R/R) HODGKIN LYMPHOMA (HL) AND CD30+ HEMATOLOGIC MALIGNANCIES
    McCarty, J. M.
    Sureda, A.
    Sweetenham, J.
    Moskowitz, C. H.
    Kennedy, D.
    Sievers, E. L.
    HAEMATOLOGICA, 2010, 95 : S28 - S28
  • [29] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J. M.
    Sievers, E. L.
    ANNALS OF ONCOLOGY, 2008, 19 : 129 - 129
  • [30] Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma
    Younes, A.
    Forero-Torres, A.
    Bartlett, N. L.
    Leonard, J. P.
    Rege, B.
    Kennedy, D. A.
    Lorenz, J. M.
    Sievers, E. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345